Frequent hypermethylation of orphan CpG islands with enhancer activity in cancer by Min Gyun Bae et al.
RESEARCH Open Access
Frequent hypermethylation of orphan CpG
islands with enhancer activity in cancer
Min Gyun Bae, Jeong Yeon Kim and Jung Kyoon Choi*
Abstract
Background: CpG islands (CGIs) are interspersed DNA sequences that have unusually high CpG ratios and GC
contents. CGIs are typically located in the promoter of protein-coding genes. They normally lack DNA
methylation but become hypermethylated and induce repression of associated genes in cancer. However, the
biological functions of non-promoter CGIs (orphan CGIs) largely remain unclear.
Results: Here, we identify orphan CGIs that do not map to the promoter of any protein-coding or non-coding
transcripts but possess chromatin and transcriptional marks that reflect enhancer activity (termed eCGIs). They
exhibit three-dimensional chromatin looping toward multiple target genes with high affinity. Intriguingly,
transcription regulators were frequently associated with such CGI-containing enhancers. Remarkably, our analyses
in cell lines and clinical tissues showed that eCGIs have more dynamic DNA methylation changes in cancer
relative to promoter CGIs. The observed eCGI hypermethylation was accompanied by a loss of enhancer marks
and transcriptional inactivation of the target genes.
Conclusion: Our results suggest that eCGIs may constitute a distinct class of enhancers and perform a more
instrumental role in tumorigenesis than typical CGIs in gene promoters.
Keywords: CpG islands, Enhancers, DNA methylation, Cancer
Background
CpG dinucleotides are frequently methylated in verte-
brate genomes. Although a significant portion of the
genome is methylated at CpG sites, CGIs are usually
unmethylated and remain transcriptionally active with
active histone marks such as H3K4me3 as a result of the
action of CxxC finger protein 1 (CFP1) [1–4]. Half of
these CGIs are located in gene promoters and play an
important role in development and cancer. For example,
important developmental genes have a promoter that
often coincides with a CGI and contains a bivalent
domain consisting of both active (H3K4me3) and repres-
sive (H3K27me3) histone marks [5]. Those genes that
have the bivalent promoter are marginally expressed in
embryonic stem cells but increase in expression level via
removal of the H3K27me3 mark during cell differenti-
ation. Furthermore, the hypermethylation of promoter
CGIs has been identified as one of the driving factors in
cancer development because it represses the expression
of tumor suppressor genes [6]. This phenomenon was
first reported in the promoter of tumor suppressor genes
in colorectal cancer and has been confirmed in many
cancer types. In addition to promoter CGI hypermethy-
lation, whole genome bisulfite sequencing has recently
revealed partially methylated domains and large hypo-
methylated domains in cancer [7].
CGIs remote from annotated promoters, located in
intergenic or intragenic regions, exhibit variable tissue-
specific methylation patterns [8, 9]. These non-promoter
CGIs are named orphan CGIs, and account for about
half of all CGIs in the human genome [3]. Although
these orphan CGIs are distal to annotated promoters,
some features are shared with promoter CGIs: marking
of H3K4me3, binding of Pol2, and production of tran-
scripts, as indicated by a Cap Analysis of Gene Expres-
sion (CAGE) [3]. Recent studies suggest that these
orphan CGIs may function as miRNA promoters [10],
and therefore the presence of an orphan CGI is an im-
portant indicator of the activity of miRNA promoters
[11]. Meanwhile, intragenic CGIs are known to act as an
alternative promoter of the genes they reside in [8].
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Although these recent studies propose that orphan
CGIs may function as promoters, here we show that not
all orphan CGIs produce transcripts, as judged by tran-
scription start sites indicated by CAGE and RNA-seq. To
understand the biological features and functions of the or-
phan CGIs that do not produce any noncoding transcripts,
we perform an integrative analysis that entails a large
amount of publicly available genomic, transcriptomic, and
epigenomic data based on K562, Mcf7, and Hmec cell lines.
Methods
ENCODE data processing
Various histone modification, transcriptome, chromatin
interactome, and DNA methylation data were down-
loaded from the ENCODE data portal (https://www.en-
codeproject.org). We downloaded bam files for various
histone modifications including H3K4me1, H3K4me2,
H3K4me3, H3K27ac, H3K27me3, H3K9me1, H3K9me3,
H3K9ac, H3K79me2, H3K36me3, and H4K20me1.
DNase I hypersensitivity site (DHS) data and transcrip-
tion factor binding data for P300, Pol2, CTCF, RAD21,
SMC3, YY1, and ZNF143 [12] were obtained as well.
Peak finding for histone modifications and DHSs was
performed using the HOMER package with -size 1000
and—minDist 2500 options.
CAGE and RNA-seq data were used to identify func-
tional transcripts. We used the transcription start sites
defined by CAGE. RNA-seq fastq files were aligned by
using Tophat and de-novo transcripts were predicted by
running StringTie [13] with its default options. Gene ex-
pression in each cell line was then determined based on
Reads Per Kilobase per Million (RPKM).
Chromatin interactome in K562 and Mcf7 cell lines
were analyzed based ona Chromatin Interaction Analysis
by paired-end tag (ChIA-pet) sequencing data for RNA
polymerase II (Pol2). In order to use significant interac-
tions only, tag counts greater or equal to 3 were taken.
Classification of CGIs
To classify CGIs based on gene annotation, we selected
genes whose refGene ID starts with “NM”. The CGIs
that are located within 1 kb of the transcription start site
of the relevant genes were labeled as promoter CGIs
(pCGIs), and the rest as orphan CGIs. The orphan CGIs
that overlap with both H3K27ac and DHS peaks in a
given cell type were then determined as active orphan
CGIs. By checking whether the active orphan CGIs over-
lap with the transcription start sites defined in the
CAGE data and the promoter of de-novo transcripts
constructed from the RNA-seq data using StringTie, we
defined eCGIs as not producing any protein-coding or
non-coding transcripts, and npCGIs (noncoding pro-
moter CGIs) as producing non-coding transcripts.
Typical enhancers were defined as H3K27ac-harboring
DHS peaks that do not overlap with the transcription
start site of de-novo transcripts detected from the CAGE
and RNA-seq data. We also excluded the H3K27ac-DHS
peaks intersecting with any CGIs. Using this method, we
found 9282, 18,528, 20,332 typical enhancers in K562,
Mcf7, and Hmec, respectively.
Target gene analysis
To check the function of the target genes of the eCGIs,
we used the ‘functional annotation clustering’ of the
Database for Annotation, Visualization and Integrated
Discovery (DAVID) with the default options. The anno-
tation clusters with the highest enrichment scores seems
to be related to transcription.
To confirm that the eCGIs target transcription regula-
tors, we used the list of 1469 sequence-specific tran-
scription factors, 117 chromatin regulators, and 296
transcription-related factors as defined in the Ani-
malTFDB data [14] for Homo sapiens. We obtained the
number of transcription regulators that are linked via
chromatin interaction to the eCGIs or typical enhancers.
To estimate the statistical significance of the overlap-
ping, we selected the same number of random DNA seg-
ments as the eCGIs and typical enhancers in each cell
type, and compared their overlapping frequencies with
that of the real eCGIs and typical enhancers.
DNA methylation analysis
To investigate DNA methylation changes in association
with the eCGIs, we used breast related normal and can-
cer pair (Hmec and Mcf7) and The Cancer Gene Atlas
(TCGA; http://cancergenome.nih.gov) data. Heatmaps
were generated using differentially methylated CpGs of
the Hmec eCGIs in both cell lines and clinical data. A
threshold of differentially methylated CpGs was deter-
mined as |differential methylation of CpGs| > 0.5 in the
cell line data and |differential methylation of CpGs| > 0.1
in the clinical data. To determine the target genes of the
Hmec eCGIs, we used the genes in the nearest proximity
to the eCGIs due to lack of Hmec ChIA-pet data. En-
richment test of tumor suppressor genes and oncogenes
were performed using Fisher-exact test. Tumor sup-
pressor genes and oncogenes used in this study were
generated by the TUSON algorithm [15]. We ex-
tracted tumor suppressor genes (484) and oncogenes
(494) with low p-value (<0.1).
Results
Classification of CGIs
We classified CGIs based on the pipeline that interro-
gates gene annotation, epigenome data, and transcrip-
tome data (Fig. 1a). To identify cell-type-specific
functional CGIs, DHS and H3K27ac patterns in K562,
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Mcf7, and Hmec cell lines were used. DHSs indicate
open regulatory sites and H3K27ac is an active histone
marker that is usually found on regulatory sites such as
promoters and enhancers. According to these criteria,
an average of 5.3 ~ 8.9 % of total CGIs were identified as
active orphan CGIs in each cell line. Because orphan
CGIs are associated with the transcription of noncoding
RNA, we checked whether they actually make tran-
scripts by analyzing CAGE and RNA-seq profiles. The
hidden Markov model was applied to the CAGE data to
identify regions that can function as a transcription start
site. In addition, RNA-seq was used to identify de-novo
transcripts. While 863 ~ 1409 CGIs were associated with
non-coding transcripts and labeled as npCGIs, 619 ~
1134 CGIs were classified as eCGIs because they did not
map to any transcription start sites despite having active
enhancer marks (Fig. 1b).
This new type of CGIs does not show genomic charac-
teristics shared with the pCGIs. First, the eCGIs are
shorter in length than the pCGIs (Additional file 1:
Figure S1A). Longer pCGIs may have been favored dur-
ing evolution because they are well-suited for multiple
transcription factors to bind and are related with pro-
moter directionality [16, 17]. Although well-established
CGI criteria based on the CpG ratio and GC percent
were used, the sequence contents of the pCGIs and
eCGIs appear to be different. Compared to the pCGIs,
the eCGIs have a lower CpG ratio and CpG percent, and
the GC percent differs statistically significantly (Additional
file 1: Figure S1B). In other words, the eCGIs have a
higher frequency of C and G, but the ratio of CpG sites,
which can be methylated, is lower in the eCGIs than
in the pCGIs. Although specific mechanisms leading
to this discrepancy are currently unknown, it is
evident that the eCGIs have distinct genomic features
as compared with the pCGIs.
Enhancer signatures of eCGIs
As described above, we predicted that the identified eCGIs
would function as enhancers because they were enriched
for H3K27ac while not mapping to any transcription start
sites. In order to corroborate our prediction, the binding
level of P300, which is a histone acetyl transferase known
as an enhancer marker, was measured. Our results verified
that the P300 binding level was similar between the eCGIs
and typical enhancers (Fig. 2a).
Next, we examined the binding level of Pol2. Studies
indicate that Pol2 transcribes not only mRNA but also
noncoding RNA, and that it binds at enhancer regions
as well. While the strongest Pol2 binding was observed
at the pCGIs, the Pol2 binding levels were similar in the
eCGIs and typical enhancers (Fig. 2).
Additionally, we examined the distribution of various
histone modifications. H3K4me1 and H3K4me3 are well-
established enhancer and promoter markers, respectively
[18]. We discovered that H3K4me1 was enriched in the
typical enhancers while H3K4me3 in the pCGIs. In eCGIs,
H3K4me1 was highly enriched, to a degree comparable
with the typical enhancers (Fig. 2c). Although the middle
point of the eCGIs showed a signature of nucleosome de-
pletion, the H3K4me1 levels were higher at the boundary
areas. The H3K4me2 and H3K4me3 distributions showed
intermediate values between the pCGIs and typical enhan-
cer (Fig. 2d, e). Previous studies suggest that CFP1 binds
to sequences with high CpG contents and recruits SETD1,
which causes trimethylation of H3K4 [4]. This might ex-
plain high H3K4me3 in eCGIs regardless of their pro-
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Fig. 1 Classification of CGIs. a Diagram of CGI classification. pCGI refers to promoter CGIs, npCGI refers to noncoding promoter CGIs, and eCGI
refers to enhancer CGIs. b The number of CGIs in each cell line
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eCGIs are similar to the typical enhancers in terms of
chromatin signatures.
We also examined other histone modifications. H3K9ac,
an active promoter marker, was high in the pCGIs.
H3K79me2, an elongation marker that is strongly
enriched in the first intron, was also high in the pCGIs.
H3K9me1, H4K20me1, and H3K36me3 showed marginal
enrichment in the typical enhancer. Because these three
histone marks are related with transcription elongation,
this may be a reflection of the typical enhancers residing
in the genebody. Repressor markers such as H3K27me3
and H3K9me3 did not show any enrichment patterns
(Additional file 1: Figure S2A).
For the eCGIs to have an enhancer function, they
should interact with the transcription start site or the pro-
moter of their target genes. Five proteins, CTCF, RAD21,
YY1, ZAN143, and SMC3, are known to govern such
chromatin interactions. All five proteins were enriched in
the eCGIs; in particular, CTCF and SMC3 signals were
much stronger in the eCGIs than in the pCGIs and the
typical enhancers (Additional file 1: Figure S2B).
Transcriptional activity of eCGIs
We next sought to test whether the eCGIs regulate the
expression of their target gene. To this end, we first
identified the eCGIs that are active specifically in K562
and Mcf7: 867 (76.5 %) were specific to K562, 352
(56.9 %) were specific to Mcf7, and 267 were common
(Fig. 3b, Additional file 1: Figure S3). We discovered that
the cell-type-specific eCGIs were associated with differ-
ential up regulation of their target gene connected via
chromatin interaction, as identified through ChIA-pet
(Fig. 3c). For example, NFIA gene, one of the nuclear
factor I family, is known as a transcription factor that
plays an important function in the brain, and ureteral
and renal development and hematopoiesis [19]. This
gene has ChIA-pet chromatin interaction with an eCGI
in K562 but no interaction in Mcf7. The expression level
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Fig. 2 Epigenetic marks reveal that the eCGIs have enhancer signatures. Distribution of epigenetic marks spanning 5 kb from the center of the
eCGIs, typical enhancers, and pCGIs, respectively. P300 and Pol2 are closely related to enhancer activity a, b and H3K4 methylations are known as
enhancer c, d or promoter e markers
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of this gene was 5.88-fold higher in K562 than in Mcf7
(Fig. 3a). These results suggest that the eCGIs we identi-
fied may function as enhancers that induce activation of
their target gene.
ECGIs as a distinct class of enhancers
We substantiated that the eCGIs have enhancer activity
by examining 1) P300 binding, 2) histone modification





Fig. 3 eCGIs are a distinct class of enhancers that regulate target gene expression. a The left panel is an example of a cell-type-specific eCGI
target, demonstrated using the WashU epigenome browser. The yellow shaded region indicates K562-specific eCGIs and the green shaded region
represents their target gene, NFIA. The right panel compares the gene expression level (RPKM) of NFIA in K562 and Mcf7 cell lines. b The diagram
shows overlapping between eCGIs and npCGIs in K562 and Mcf7 cell lines. c Expression fold change of genes targeted by each cell-type-specific eCGI.
d ChIA-pet signal distribution in K562 (left) and Mcf7 (right) cell lines. The P-value was calculated by the Wilcoxon signed-rank test. e Histogram
showing the proportion of enhancers targeting one gene (single) and two or more genes (multiple)
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4) transcriptional activity. We next concentrated on dif-
ferences between the eCGIs and typical enhancers. We
first examined the features of chromatin interaction in-
volving either eCGI or a typical enhancer. The average
ChIA-pet tag count for each pair of the eCGIs and their
connected promoters was significantly higher than that
for each pair of typical enhancers and their promoters
(Fig. 3d). The eCGIs were more active than the typical
enhancers not only in terms of interaction strength but
also in terms of the number of the interactions (Fig. 3e).
Thus, the eCGIs may play a more pivotal role in regulat-
ing gene expression than the typical enhancers. We ex-
amined Gene Ontology to characterize the target genes
of the eCGIs. The strongest functional enrichment was
observed for transcription in both K562 and Mcf7
(Fig. 4a). For example, the NFIA gene described above is
known to play diverse roles as a transcription factor
across many cell types (Fig. 3a). For a statistical test, we
performed 1000 permutations to obtain the expected
number of chromatin interactions between transcription
factors and the eCGIs or typical enhancers. The same
number of random DNA segments as the eCGIs or typ-
ical enhancers in K562 and Mcf7 were generated. We
then examined the number of links with transcription
regulators such as sequence-specific transcription fac-
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Fig. 4 eCGIs primarily target transcription regulators. a The gene clusters with the highest enrichment score detected by the DAVID’s functional
annotation clustering in K562 (left) and Mcf7 (right). P values were transformed by –log10. All clustering lists are provided in Additional file 1:
Table S2. b, c The distribution of the number of transcription regulators associated with random DNA fragments (black line). The permutation was
repeated 1000 times. Red lines indicate the number of transcription regulators associated with the eCGIs (upper) or typical enhancers (lower) in
K562 (B) and in Mcf7 (C)
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factors as defined in the AnimalTFDB [14]. As a result,
in both cell lines, the eCGIs were more frequently asso-
ciated with the transcription regulators than expected by
chance (Fig. 4b, c). In contrast, the typical enhancers
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Fig. 5 Dynamic tumorigenic changes of DNA methylation in the eCGIs. a Heatmap showing aberrant DNA methylation of the eCGIs in Mcf7 cell
line (left) and clinical cancer data (right). b Boxplots showing that the eCGIs are more hypermethylated than the pCGIs in both cell lines (left) and
clinical data (right). c Down-regulation of the target genes of the hypermethylated eCGIs in Mcf7 cell line and clinical cancer data. d Global loss
of DHS and H3K27ac signals at hypermethylated eCGIs in Mcf7. e Fisher-exact test for enrichment of target genes of hypermethylated eCGIs on
tumor suppressor genes
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Previous studies have identified super enhancers, also
known as stretch enhancers, which are large clusters of
transcriptional enhancers that drive expression of genes
that define cell identity [20, 21]. We checked whether
the eCGIs we identified here are coincident with the
super enhancers. In terms of physical overlapping in
K562, only a small fraction (9.7 %) of the eCGIs was pre-
viously identified as super enhancers (Additional file 1:
Figure S4A). H3K27ac is the major histone mark that is
used to identify super enhancers. The H3K27ac levels
were much lower in the eCGIs than in the super en-
hancers (Additional file 1: Figure S4B). Taken altogether,
the results suggest that the eCGIs constitute a new type
of enhancers that are different from typical enhancers or
super enhancers.
Dynamic tumorigenic changes of DNA methylation at
eCGIs
In cancer, tumor suppressor genes are inactivated by pCGI
hypermethylation. To study whether DNA methylation at
eCGIs play a role in cancer, we analyzed the ENCODE
methylation data of Hmec and Mcf7 cell lines and the
TCGA breast-normal cancer data. The overall pattern of
the heatmaps showed that the methylation increases at
the eCGIs in cancer cells when compared to normal cells
and the differential DNA methylation levels across the cell
lines and clinical data were significantly higher in the
eCGIs than in the pCGIs (Fig. 5a, b). This may indicate
that particular eCGIs are hypermethylated to a higher de-
gree than an average pCGI in a cancer-specific manner.
This aberrant DNA methylation in the eCGIs may play a
more critical role in tumorigenesis than that in the pCGIs.
To test whether the oncogenic DNA methylation
changes in the eCGIs affect regulatory activities and ul-
timately gene expression levels, we selected eCGIs with
a > 0.5 DNA methylation increase in Mcf7 compared to
Hmec, and those with a > 0.1 DNA methylation increase
in clinical cancer samples compared to normal samples.
The target gene expression level of hypermethylated
eCGIs was lower in Mcf7 and clinical cancer data,
suggesting transcriptional silencing effects of eCGI
hypermethylation in cancer (Fig. 5c). To study the mech-
anism of transcriptional silencing effects of eCGI hyper-
methylation, we used DHS and H3K27ac signal in Hmec
and Mcf7. The hypemethylation of these eCGIs was ac-
companied by a significant reduction in the DHS and
H3K27ac signals (Fig. 5d), suggesting that some eCGIs
function as enhancers in normal cells but lose their en-
hancer function due to DNA hypermethylation in cancer.
To test that genes silenced by eCGI hypermethylation are
tumor suppressor genes, we performed Fisher-exact test
using 484 predicted tumor suppressor genes and 494 pre-
dicted oncogenes (Fig. 5e). The enrichment of targeted
tumor suppressor genes by hypermethylated eCGIs is
higher than the enrichment of targeting tumor suppressor
genes by random regions and targeting oncogenes by
eCGIs. This indicates that eCGI hypermethylation may in-
activate tumor suppressor genes by removing enhancer
activity.
Discussion
An enhancer is a distal regulatory region that activates
the expression of remote genes. A global epigenome
study reveals that enhancers usually are bound by P300
proteins, and possess H3K4me1 and H3K27ac marks
but not H3K4me3, which is known as a promoter
marker. However, recent studies show that some active
enhancers possess H3K4me3. Also, eRNAs that are
made by polymerase II bound at enhancer regions
stabilize enhancer-promoter looping. Based on the fact
that eRNAs are transcribed bidirectionally, active en-
hancers were detected using the bidirectional CAGE dis-
tribution through FANTOM5 [22].
CpG islands are DNA sequences having high CpG ra-
tios and GC contents. About half of CpG islands are lo-
cated around transcription start site of protein coding
genes. Promoters with CpG islands have higher expres-
sion than non-CpG island promoters and housekeeping
genes usually have promoter CpG islands. These pro-
moter CpG islands are usually hypermethylated during
tumorigenesis and inactivate tumor suppressor genes.
However, the other half of CpG islands that are not lo-
cated at promoter regions have not been studied exten-
sively. Some studies reported that some orphan CpG
islands are promoters of noncoding RNAs, such as
microRNA and lncRNA, through CAGE and RNA-seq
analyses. Further study is still required.
Here we identified that some of these orphan CGIs
possess the characteristics of enhancers, including
H3K4me1, H3K27ac, P300 binding, three-dimensional
interaction, and transcriptional activity. These eCGIs dif-
fer from the typical promoter CGIs not only in terms of
genomic features, such as CGI size and sequence con-
tents, but also in terms of epigenomic features such as
the intensity patterns of particular histone modifications.
The enhancers harboring a CGI were also different from
typical enhancers. They are capable of interacting with
multiple target genes with a higher chromatin inter-
action affinity. Intriguingly, most of these targeted genes
are transcription regulators. Thus, the eCGIs appear to
play a more important role in the regulatory network. Im-
portantly, the eCGIs tend to be hypermethylated during
cancer development in both cell lines and clinical breast
cancer samples. Although this is a well established feature
of the typical promoter CGIs, the degree of DNA methyla-
tion changes is greater for the eCGIs than the typical
CGIs. Because of hypermethylation in eCGIs, enhancer
signatures disappear and down regulate target genes.
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Conclusion
We identified eCGIs using various epigenomic and tran-
scriptomic features based on H3K27ac sequencing,
RNA-seq, and CAGE data. This method may produce
false positives even though eCGIs that we found have
enhancer activity. To overcome this problem, STARR-
seq [23], which can detect enhancers quantitatively, may
be useful to find eCGIs. We also found that eCGIs are
frequently hypermethylated in both cell lines and clinical
tissues. This suggests that orphan CGIs with enhancer
activity in a given cell type should be considered a novel
biomarker in cancer diagnosis and treatment.
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